SVB Securities analyst Thomas Smith maintained a Hold rating on Landos Biopharma (LABP – Research Report) on May 12 and set a price target of $1.00. The company’s shares closed yesterday at $0.29.
Smith covers the Healthcare sector, focusing on stocks such as Immunic, MoonLake Immunotherapeutics, and Dice Therapeutics. According to TipRanks, Smith has an average return of 39.6% and a 50.60% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Landos Biopharma with a $1.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Landos Biopharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $5.16 million. In comparison, last year the company had a GAAP net loss of $15.11 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need.
Read More on LABP:
- UPDATE — Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
- Landos Biopharma reports Q4 EPS (13c), consensus (19c)
- Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
